

**Discovery Services** 

## **PRODUCT DATASHEET**

### ChemiScreen<sup>™</sup> PAC<sub>1</sub>-Long Membrane Preparation

| CATALOG NUMBER: | HTS114M | QUANTITY: | 200 units |
|-----------------|---------|-----------|-----------|
|                 |         |           |           |

LOT NUMBER: 2093604 VOLUME/CONCENTRATION: 1 mL, 1 mg/mL

PACAP (pituitary adenylyl cyclase-activating peptide) is a peptide that exists in 2 forms, 27 **BACKGROUND:** or 38 amino acids, and is related to vasoactive intestinal peptide (VIP). Three related class B GPCRs, PAC<sub>1</sub>, VPAC<sub>1</sub> and VPAC<sub>2</sub>, bind to PACAP; however, VPAC<sub>1</sub> and VPAC<sub>2</sub> have a much higher affinity for VIP than does PAC<sub>1</sub> (Vaudry et al., 2000). Several splice variants of PAC<sub>1</sub> result in proteins that differ at the N-terminus and third intracellular loop; these variants differ in their affinities for PACAP and abilities to activate Gq and Gs. High expression of PAC<sub>1</sub> is observed in the CNS and the adrenal medulla. Studies with PAC<sub>1</sub>null mice indicate that PAC<sub>1</sub> plays important roles in regulation of circadian rhythms, neutrophil migration, and pulmonary vascular tone (Hannibal et al., 2001; Martinez et al., 2005: Otto et al., 2004). PAC1-long membrane preparations are crude membrane preparations made from our proprietary stable recombinant cell lines to ensure high-level of GPCR surface expression; thus, they are ideal HTS tools for screening of antagonists of PAC<sub>1</sub>-long interactions with PACAP27. The membrane preparations exhibit a Kd of 2.7 nM for [1251]-PACAP27. With 5 µg/well PAC1-long Membrane Prep and 0.75 nM [1251]-PACAP27, a greater than 12-fold signal-to-background ratio was obtained.

**APPLICATIONS:** 

Radioligand binding assay





Eurofins Pharma Bioanalytics Services US Inc. 6 Research Park Drive St Charles MO 63304 USA T +1 844 522 7787 F +1 636 362 7131 www.eurofins.com



## **Discovery Services**



**Figure 2. Competition binding for PAC<sub>1</sub>-long.** PAC<sub>1</sub>-long Membrane Preparation (5 or 10  $\mu$ g/well) or Wild-Type Chem-1 membrane preparation (Catalog # HTS000MC1) was incubated with 0.75 nM [1251]-PACAP27 and increasing concentrations of unlabeled PACAP27, and more than 12- fold signal:background was obtained. Representative sample data.

**SPECIFICATIONS:** 1 unit = 5 µg

B<sub>max:</sub> 52.0 pmol/mg K<sub>d</sub>: 2.7nM Signal:background: >12-fold

**TRANSFECTION:** Human ADCYAP1R1 cDNA encoding the long isoform of PAC<sub>1</sub> (Accession number NM\_001118)

Species: Human

**HOST CELLS:** Chem-1, an adherent mammalian cell line without any endogenous PAC<sub>1</sub> expression.

**RECOMMENDED ASSAY CONDITIONS:** Membranes are mixed with radioactive ligand and unlabeled competitor (see Figures 1 and 2 for concentrations tested) in binding buffer in a nonbinding 96-well plate, and incubated for 1-2 h. Prior to filtration, a GF/C 96-well filter plate is coated with 0.33% polyethyleneimine for 30 min, then washed with 50mM HEPES, pH 7.4, 0.5% BSA. Binding reaction is transferred to the filter plate, and washed 3 times (1 mL per well per wash) with Wash Buffer. The plate is dried and counted.

Binding buffer: 50 mM Hepes, pH 7.4, 5 mM MgCl2, 1 mM CaCl2, 0.2% BSA, filtered and stored at 4°C

Radioligand: [125I] PACAP27 (Perkin Elmer # NEX294)

Wash Buffer: 50 mM Hepes, pH 7.4, 500mM NaCl, 0.1% BSA, filtered and stored at 4°C. One package contains enough membranes for at least 200 assays (units), where a unit is the amount of membrane that will yield greater than 12-fold signal:background with 125I-labeled PACAP27 at 0.75 nM.

PRESENTATION:Liquid in packaging buffer: 50 mM Tris pH 7.4, 10% glycerol and 1% BSA with no<br/>preservatives.<br/>Packaging method: Membrane proteins were adjusted to the indicated concentration in 1 ml<br/>packaging buffer, rapidly frozen, and stored at -80°C.

## **STORAGE/HANDLING:** Store at –70°C. Product is stable for at least 6 months from the date of receipt when stored as directed. Do not freeze and thaw.

#### **REFERENCES:**

1) Hannibal J et al. (2001) Dissociation between light-induced phase shift of the circadian rhythm and clock gene expression in mice lacking the pituitary adenylate



## **Discovery Services**

cyclase activating polypeptide type I receptor. J. Neurosci. 21: 4883-4890.

- 2) Martinez C et al. (2005) Analysis of the role of the PAC1 receptor in neutrophil recruitment, acute-phase response, and nitric oxide production in septic shock. J. Leukoc. Biol. 77(5):729-38.
- Otto C et al. (2004) Pulmonary hypertension and right heart failure in pituitary adenylate cyclase-activating polypeptide type I receptor-deficient mice. Circulation 110: 3245-3251.
- 4) Vaudry D et al. (2000) Pituitary adenylate cyclase-activating polypeptide and its receptors: from structure to functions. Pharmacol. Rev. 52: 269-324.

# FOR RESEARCH USE ONLY; NOT FOR USE IN DIAGNOSTIC PROCEDURES. NOT FOR HUMAN OR ANIMAL CONSUMPTION

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

No part of these works may be reproduced in any form without permission in writing.

Eurofins Pharma Bioanalytics Services US Inc. is an independent member of Eurofins Discovery Services